The immunocompromised adult patient and surgery

Best Practice and Research: Clinical Anaesthesiology

Volumn 22, Issue 3, 2008, Pages 585-609

  Littlewood, Keith E ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

HIV infections; humans; immunosuppression; neoplasms; organ transplantation; perioperative care; postoperative complications; surgical procedures; survival rate; treatment outcome

Indexed keywords

ANESTHETIC AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; DACLIZUMAB; EFALIZUMAB; EVEROLIMUS; HALOTHANE; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; ISOFLURANE; KETAMINE; METHADONE; METHYLPREDNISOLONE; MORPHINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OPIATE; PENTOBARBITAL; PREDNISONE; PROPOFOL; PROTEINASE INHIBITOR; RAPAMYCIN; REMIFENTANIL; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONAMIDE; TACROLIMUS; THYMOCYTE ANTIBODY; TRIMETHOPRIM; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADRENAL INSUFFICIENCY; ADULT; ANALGESIA; ANAPHYLAXIS; ANEMIA; ANESTHESIA INDUCTION; ANESTHESIOLOGICAL TECHNIQUES; ANOREXIA; ARTHRALGIA; ASCITES; AUTOIMMUNE DISEASE; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; BONE NECROSIS; BRONCHIOLITIS OBLITERANS; BRONCHOSPASM; CAPILLARY LEAK SYNDROME; CARDIOMYOPATHY; CARDIOTOXICITY; CATARACT; CHOLESTASIS; CONFUSION; CORONARY ARTERY SPASM; COUGHING; CYTOMEGALOVIRUS INFECTION; DERMATITIS; DIGESTIVE SYSTEM ULCER; DISEASE CLASSIFICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; EPIDURAL ANESTHESIA; FLUID RETENTION; GASTROINTESTINAL OBSTRUCTION; GENERAL ANESTHESIA; GLUCOSE INTOLERANCE; GRAFT VERSUS HOST REACTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; HEMOLYTIC UREMIC SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERNATREMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; HYPOTHYROIDISM; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; IMMUNOPATHOGENESIS; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JAUNDICE; LEUKEMOGENESIS; LEUKOPENIA; LIVER FAILURE; LIVER FIBROSIS; LIVER NECROSIS; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; LUNG EDEMA; LUNG EMBOLISM; LUNG FIBROSIS; LUNG INFILTRATE; LUNG TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MENTAL HEALTH; METABOLIC ACIDOSIS; METHEMOGLOBINEMIA; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OLIGURIA; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PANCREATITIS; PATIENT CARE; PERICARDIAL EFFUSION; PERIOPERATIVE PERIOD; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; QT PROLONGATION; RAYNAUD PHENOMENON; REVIEW; RHABDOMYOLYSIS; SEIZURE; SEPSIS; SIDE EFFECT; SLEEP APNEA SYNDROME; SPINAL ANESTHESIA; STEVENS JOHNSON SYNDROME; SUPRAVENTRICULAR TACHYCARDIA; SURGICAL RISK; THROMBOCYTOPENIA; THROMBOSIS; TREMOR; VEIN THROMBOSIS; VERTIGO; VOCAL CORD PARALYSIS;

ADULT; ANESTHESIA; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; NEOPLASMS; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; SURGICAL PROCEDURES, OPERATIVE; TRANSPLANTATION IMMUNOLOGY;

EID: 49449117354     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2008.05.005     Document Type: Review

References (147)

1. Nieuwkerk P.T., Hillebrand-Haverkort M.E., Vriesendorp R., et al. Quality of life after starting highly active antiretroviral therapy for chronic HIV-1 infection at different CD4 cell counts. Journal of Acquired Immune Deficiency Syndromes: JAIDS 45 5 (2007) 600-601
2. van Sighem A.I., van de Wiel M.A., Ghani A.C., et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. [see comment]. AIDS 17 15 (2003) 2227-2236
3. Hariri S., and McKenna M.T. Epidemiology of human immunodeficiency virus in the United States. Clinical Microbiology Reviews 20 3 (2007) 478-488
4. Tapper M.L., Daar E.S., Piliero P.J., et al. Strategies for initiating combination antiretroviral therapy. Aids Patient Care STDS 19 4 (2005) 224-238
5. Hofman P., and Nelson A.M. The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update. Current Medicinal Chemistry 13 26 (2006) 3121-3132
6. Corti M., Villafane M.F., Ambroggi M., et al. Soft tissue abscess and lymphadenitis due to Mycobacterium avium complex as an expression of immune reconstitution inflammatory syndrome after a second scheme of highly active antiretroviral therapy. Revista do Instituto de Medicina Tropical de Sao Paulo 49 4 (2007) 267-270
7. Pignataro P., Rocha Ada S., Nery J.A., et al. Leprosy and AIDS: two cases of increasing inflammatory reactions at the start of highly active antiretroviral therapy. European Journal of Clinical Microbiology & Infectious Diseases 23 5 (2004) 408-411
8. Morris D.G., Jasmer R.M., Huang L., et al. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest 124 3 (2003) 929-935
9. French M.A., Lewin S.R., Dykstra C., et al. Graves' disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. AIDS Research and Human Retroviruses 20 2 (2004) 157-162
10. Miralles P., Berenguer J., Lacruz C., et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 15 14 (2001) 1900-1902
11. Zandman-Goddard G., and Shoenfeld Y. HIV and autoimmunity. Autoimmunity Reviews 1 6 (2002) 329-337
12. Mondy K., Yarasheski K., Powderly W.G., et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clinical Infectious Diseases 36 4 (2003) 482-490
13. Luther J., and Glesby M.J. Dermatologic adverse effects of antiretroviral therapy: recognition and management. American Journal of Clinical Dermatology 8 4 (2007) 221-233
14. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nature Reviews Drug Discovery 2 8 (2003) 624-634
15. Schambelan M., Benson C.A., Carr A., et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. Journal of Acquired Immune Deficiency Syndromes: JAIDS 31 3 (2002) 257-275
16. Geddes R., Knight S., Moosa M.Y., et al. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. South African Medical Journal Suid-Afrikaanse Tydskrif Vir Geneeskunde 96 8 (2006) 722-724
17. Wester C.W., Okezie O.A., Thomas A.M., et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes: JAIDS 46 3 (2007) 318-322
18. Stankov M.V., and Behrens G.M. HIV-therapy associated lipodystrophy: experimental and clinical evidence for the pathogenesis and treatment. Endocrine, Metabolic & Immune Disorders Drug Targets 7 4 (2007) 237-249
19. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. Journal of Neurovirology 8 Suppl 2 (2002) 115-121
20. Powderly W.G. Long-term exposure to lifelong therapies. Journal of Acquired Immune Deficiency Syndromes: JAIDS 29 Suppl 1 (2002) S28-S40
21. Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Progress in Cardiovascular Diseases 43 2 (2000) 151-170
22. Lewis W., Haase C.P., Raidel S.M., et al. Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Laboratory Investigation 81 11 (2001) 1527-1536
23. Milinkovic A., and Martinez E. Current perspectives on HIV-associated lipodystrophy syndrome. The Journal of Antimicrobial Chemotherapy 56 1 (2005) 6-9
24. Florescu D., and Kotler D.P. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antiviral Therapy 12 2 (2007) 149-162
25. Balasubramanyam A., Sekhar R.V., Jahoor F., et al. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'. Current Opinion in Lipidology 15 1 (2004) 59-67
26. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Journal of Hepatology 44 1 Suppl (2006) S132-S139
27. de Silva T.I., Post F.A., Griffin M.D., et al. HIV-1 infection and the kidney: an evolving challenge in HIV medicine. Mayo Clinic Proceedings 82 9 (2007) 1103-1116
28. Atta M.G., Gallant J.E., Rahman M.H., et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrology Dialysis Transplantation 21 10 (2006) 2809-2813
29. Reveille J.D., and Williams F.M. Infection and musculoskeletal conditions: rheumatologic complications of HIV infection. Best Practice & Research in Clinical Rheumatology 20 6 (2006) 1159-1179
30. Moyle G. Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity. AIDS Reviews 4 1 (2002) 13-20
31. Lundy J. Anesthesia and surgery: a double-edged sword for the cancer patient. Journal of Surgical Oncology 14 1 (1980) 61-65
32. Weesner K.M., Bledsoe M., Chauvenet A., et al. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 68 2 (1991) 435-438
33. Thorne A.C., Orazem J.P., Shah N.K., et al. Isoflurane versus fentanyl: hemodynamic effects in cancer patients treated with anthracyclines. Journal of Cardiothoracic and Vascular Anesthesia 7 3 (1993) 307-311
34. Burrows F.A., Hickey P.R., and Colan S. Perioperative complications in patients with anthracycline chemotherapeutic agents. Canadian Anaesthetists' Society Journal 32 2 (1985) 149-157
35. Gorton H., Wilson R., Robinson A., et al. Survivors of childhood cancers: implications for obstetric anaesthesia. British Journal of Anaesthesia 85 6 (2000) 911-913
36. Zaniboni A., Prabhu S., and Audisio R.A. Chemotherapy and anaesthetic drugs: too little is known. Lancet Oncology 6 3 (2005) 176-181
37. Chabner B.A., Amrein P.C., Druker B.J., et al. Antineoplastic agents. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics (2006), McGraw-Hill, Inc, New York, NY p. Chapter 51
38. Andreyev H.J. Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clinical Oncology (Royal College of Radiologists (Great Britain)) 19 10 (2007) 790-799
39. Kong F.M., Pan C., Eisbruch A., et al. Physical models and simpler dosimetric descriptors of radiation late toxicity. Seminars in Radiation Oncology 17 2 (2007) 108-120
40. Wang J., Boerma M., Fu Q., et al. Significance of endothelial dysfunction in the pathogenesis of early and delayed radiation enteropathy. [see comment]. World Journal of Gastroenterology 13 22 (2007) 3047-3055
41. Bird B.R., and Swain S.M. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clinical Cancer Research 14 1 (2008) 14-24
42. Carver J.R., Shapiro C.L., Ng A., et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. [see comment]. Journal of Clinical Oncology 25 25 (2007) 3991-4008
43. Ghafoori P., Marks L.B., Vujaskovic Z., et al. Radiation-induced lung injury. Assessment, management, and prevention. Oncology (Williston Park) 22 1 (2008) 37-47 [discussion: 52-3]
44. Madani I., De Ruyck K., Goeminne H., et al. Predicting risk of radiation-induced lung injury. Journal of Thoracic Oncology 2 9 (2007) 864-874
45. Goldiner P.L., Carlon G.C., Cvitkovic E., et al. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. British Medical Journal 1 6128 (1978) 1664-1667
46. LaMantia K.R., Glick J.H., and Marshall B.E. Supplemental oxygen does not cause respiratory failure in bleomycin-treated surgical patients. Anesthesiology 60 1 (1984) 65-67
47. Matalon S., Harper W.V., Nickerson P.A., et al. Intravenous bleomycin does not alter the toxic effects of hyperoxia in rabbits. Anesthesiology 64 5 (1986) 614-619
48. Donat S.M., and Levy D.A. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?. The Journal of Urology 160 4 (1998) 1347-1352
49. Hopf H.W., and Rollins M.D. Wounds: an overview of the role of oxygen. Antioxidants & Redox Signaling 9 8 (2007) 1183-1192
50. Panjrath G.S., and Jain D. Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging. Journal of Nuclear Cardiology 13 3 (2006) 415-426
51. Xin Y.F., Zhou G.L., Deng Z.Y., et al. Protective effect of Lycium barbarum on doxorubicin-induced cardiotoxicity. Phytotherapy Research: PTR 21 11 (2007) 1020-1024
52. Outomuro D., Grana D.R., Azzato F., et al. Adriamycin-induced myocardial toxicity: new solutions for an old problem?. International Journal of Cardiology 117 1 (2007) 6-15
53. Kelishomi R.B., Ejtemaeemehr S., Tavangar S.M., et al. Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Toxicology 243 1-2 (2008) 96-104
54. Morandi P., Ruffini P.A., Benvenuto G.M., et al. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplantation 35 4 (2005) 323-334
55. Berliner S., Rahima M., Sidi Y., et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Investigation 8 6 (1990) 583-586
56. Meinardi M.T., Gietema J.A., van der Graaf W.T., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. Journal of Clinical Oncology 18 8 (2000) 1725-1732
57. Gharib M.I., and Burnett A.K. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. European Journal of Heart Failure 4 3 (2002) 235-242
58. Alter P., Herzum M., Soufi M., et al. Cardiotoxicity of 5-fluorouracil. Cardiovascular & Hematological Agents in Medicinal Chemistry 4 1 (2006) 1-5
59. Perik P.J., de Korte M.A., van Veldhuisen D.J., et al. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Review of Anticancer Therapy 7 12 (2007) 1763-1771
60. Telli M.L., Hunt S.A., Carlson R.W., et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. Journal of Clinical Oncology 25 23 (2007) 3525-3533
61. Mitchell M.S. Combinations of anticancer drugs and immunotherapy. Cancer Immunology, Immunotherapy: CII 52 11 (2003) 686-692
62. Au W.Y., and Kwong Y.L. Arsenic trioxide: safety issues and their management. Acta Pharmacologica Sinica 29 3 (2008) 296-304
63. Owczuk R., Wujtewicz M.A., Sawicka W., et al. Is prolongation of the QTc interval during isoflurane anaesthesia more prominent in women pretreated with anthracyclines for breast cancer?. British Journal of Anaesthesia 92 5 (2004) 658-661
64. Floyd J., Mirza I., Sachs B., et al. Hepatotoxicity of chemotherapy. Seminars in Oncology 33 1 (2006) 50-67
65. King P.D., and Perry M.C. Hepatotoxicity of chemotherapy. Oncologist 6 2 (2001) 162-176
66. Treon S.P., and Chabner B.A. Concepts in use of high-dose methotrexate therapy. Clinical Chemistry 42 8 Pt 2 (1996) 1322-1329
67. Delaney P. Vincristine-induced laryngeal nerve paralysis. Neurology 32 11 (1982) 1285-1288
68. Annino Jr. D.J., MacArthur C.J., and Friedman E.M. Vincristine-induced recurrent laryngeal nerve paralysis. Laryngoscope 102 11 (1992) 1260-1262
69. Burns B.V., and Shotton J.C. Vocal fold palsy following vinca alkaloid treatment. The Journal of Laryngology and Otology 112 5 (1998) 485-487
70. Ryan S.P., DelPrete S.A., Weinstein P.W., et al. Low-dose vincristine-associated bilateral vocal cord paralysis. Connecticut Medicine 63 10 (1999) 583-584
71. Harris C.M., and Blanchaert R.H. Bilateral recurrent laryngeal nerve palsy resulting from treatment with vincristine. Journal of Oral and Maxillofacial Surgery 64 4 (2006) 738-739
72. Praveen C.V., and De Lord C.F. Bilateral vocal fold paralysis following treatment with vincristine. The Journal of Laryngology and Otology 120 5 (2006) 423
73. Rezvani K., Bain B.J., and Coulter C.A. Loss of singing ability caused by vincristine. Clinical and Laboratory Haematology 20 1 (1998) 47-48
74. von Schlippe M., Fowler C.J., and Harland S.J. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. British Journal of Cancer 85 6 (2001) 823-826
75. Hebl J.R., Horlocker T.T., and Pritchard D.J. Diffuse brachial plexopathy after interscalene blockade in a patient receiving cisplatin chemotherapy: the pharmacologic double crush syndrome. Anesthesia and Analgesia 92 1 (2001) 249-251
76. 2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD. In,
77. Toledo-Pereyra L.H., and Toledo A.H. 1954. Journal of Investigative Surgery 18 6 (2005) 285-290
78. Atala A., Bauer S.B., Soker S., et al. Tissue-engineered autologous bladders for patients needing cystoplasty. [see comment]. Lancet 367 9518 (2006) 1241-1246
79. Cullen D.K., Stabenfeldt S.E., Simon C.M., et al. In vitro neural injury model for optimization of tissue-engineered constructs. Journal of Neuroscience Research 85 16 (2007) 3642-3651
80. Petersen M.C., Lazar J., Jacob H.J., et al. Tissue engineering: a new frontier in physiological genomics. Physiological Genomics 32 1 (2007) 28-32
81. Huang J.H., Zager E.L., Zhang J., et al. Harvested human neurons engineered as live nervous tissue constructs: implications for transplantation. Laboratory investigation. Journal of Neurosurgery 108 2 (2008) 343-347
82. Gunthart M., and Kearns-Jonker M. Gene therapy for the induction of chimerism and transplant tolerance. Current Gene Therapy 7 6 (2007) 411-420
83. Miao C.H. Recent advances in immune modulation. Current Gene Therapy 7 5 (2007) 391-402
84. Thompson C., Neal M., and Peters N. Importance of transplantation history in ABO discrepancies. Clinical Laboratory Science 18 1 (2005) 5-7
85. Pelletier S.J., Crabtree T.D., Gleason T.G., et al. Characteristics of infectious complications associated with mortality after solid organ transplantation. Clinical Transplantation 14 4 Pt 2 (2000) 401-408
86. Dharnidharka V.R., Stablein D.M., and Harmon W.E. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. American Journal of Transplantation 4 3 (2004) 384-389
87. Freund M., and Kleine H.D. The role of GM-CSF in infection. Infection 20 Suppl 2 (1992) S84-S92
88. Meropol N.J., Wood D.E., Nemunaitis J., et al. Randomized, placebo-controlled, multicenter trial of granulocyte-macrophage colony-stimulating factor as infection prophylaxis in oncologic surgery. Leukine Surgical Prophylaxis Research Group. Journal of Clinical Oncology 16 3 (1998) 1167-1173
89. Oosterling S.J., Mels A.K., Geijtenbeek T.B., et al. Preoperative granulocyte/macrophage colony-stimulating factor (GM-CSF) increases hepatic dendritic cell numbers and clustering with lymphocytes in colorectal cancer patients. Immunobiology 211 6-8 (2006) 641-649
90. Kirman I., Belizon A., Balik E., et al. Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery. European Journal of Surgical Oncology 33 10 (2007) 1169-1176
91. Mannick J.A., Rodrick M.L., and Lederer J.A. The immunologic response to injury. [see comment]. Journal of the American College of Surgeons 193 3 (2001) 237-244
92. Puig N.R., Ferrero P., Bay M.L., et al. Effects of sevoflurane general anesthesia: immunological studies in mice. International Immunopharmacology 2 1 (2002) 95-104
93. Elena G., Amerio N., Ferrero P., et al. Effects of repetitive sevoflurane anaesthesia on immune response, select biochemical parameters and organ histology in mice. Laboratory Animals 37 3 (2003) 193-203
94. Inada T., Yamanouchi Y., Jomura S., et al. Effect of propofol and isoflurane anaesthesia on the immune response to surgery. Anaesthesia 59 10 (2004) 954-959
95. Chen H.I., Hsieh N.K., Kao S.J., et al. Protective effects of propofol on acute lung injury induced by oleic acid in conscious rats. Critical Care Medicine 36 4 (2008) 1214-1221
96. Marik P.E. Propofol: an immunomodulating agent. Pharmacotherapy 25 5 Pt 2 (2005) 28S-33S
97. Herr D.L., Kelly K., Hall J.B., et al. Safety and efficacy of propofol with EDTA when used for sedation of surgical intensive care unit patients. Intensive Care Medicine 26 Suppl 4 (2000) S452-S462
98. Fuentes J.M., Talamini M.A., Fulton W.B., et al. General anesthesia delays the inflammatory response and increases survival for mice with endotoxic shock. Clinical & Vaccine Immunology: CVI 13 2 (2006) 281-288
99. Beilin B., Rusabrov Y., Shapira Y., et al. Low-dose ketamine affects immune responses in humans during the early postoperative period. British Journal of Anaesthesia 99 4 (2007) 522-527
100. Swanton B.J., and Shorten G.D. Anti-inflammatory effects of local anesthetic agents. International Anesthesiology Clinics 41 1 (2003) 1-19
101. Lahat A., Horin S.B., Lang A., et al. Lidocaine down-regulates nuclear factor-kappaB signalling and inhibits cytokine production and T cell proliferation. Clinical and Experimental Immunology 152 2 (2008) 320-327
102. Delogu G., Moretti S., Antonucci A., et al. Apoptogenic effect of fentanyl on freshly isolated peripheral blood lymphocytes. Journal of Trauma-Injury Infection & Critical Care 57 1 (2004) 75-81
103. Martucci C., Panerai A.E., and Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 110 1-2 (2004) 385-392
104. Sacerdote P. Opioids and the immune system. Palliative Medicine 20 Suppl 1 (2006) s9-s15
105. Yeager M.P., Procopio M.A., DeLeo J.A., et al. Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans. Anesthesia and Analgesia 94 1 (2002) 94-99
106. Sharp B.M. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behavior and Immunity 20 1 (2006) 9-14
107. Angele M.K., and Faist E. Clinical review: immunodepression in the surgical patient and increased susceptibility to infection. [see comment]. Critical Care 6 4 (2002) 298-305
108. Vallejo R., Hord E.D., Barna S.A., et al. Perioperative immunosuppression in cancer patients. Journal of Environmental Pathology, Toxicology and Oncology 22 2 (2003) 139-146
109. Kehlet H. Manipulation of the metabolic response in clinical practice. World Journal of Surgery 24 6 (2000) 690-695
110. de Leon-Casasola O.A. Immunomodulation and epidural anesthesia and analgesia. Regional Anesthesia 21 6 Suppl (1996) 24-25
111. Moen V., Dahlgren N., and Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. [see comment]. Anesthesiology 101 4 (2004) 950-959
112. Wang L.P., Hauerberg J., and Schmidt J.F. Incidence of spinal epidural abscess after epidural analgesia: a national 1-year survey. Anesthesiology 91 6 (1999) 1928-1936
113. Wada H., Seki S., Takahashi T., et al. Combined spinal and general anesthesia attenuates liver metastasis by preserving TH1/TH2 cytokine balance. Anesthesiology 106 3 (2007) 499-506
114. Ciepichal J., and Kubler A. Effect of general and regional anesthesia on some neutrophil functions. Archivum Immunologiae et Therapiae Experimentalis 46 3 (1998) 183-192
115. Le Cras A.E., Galley H.F., and Webster N.R. Spinal but not general anesthesia increases the ratio of T helper 1 to T helper 2 cell subsets in patients undergoing transurethral resection of the prostate. Anesthesia and Analgesia 87 6 (1998) 1421-1425
116. Kawasaki T., Ogata M., Kawasaki C., et al. Effects of epidural anaesthesia on surgical stress-induced immunosuppression during upper abdominal surgery. [see comment]. British Journal of Anaesthesia 98 2 (2007) 196-203
117. Walker W.S., Codispoti M., Soon S.Y., et al. Long-term outcomes following VATS lobectomy for non-small cell bronchogenic carcinoma. European Journal of Cardio-thoracic Surgery 23 3 (2003) 397-402
118. Roviaro G., Varoli F., Vergani C., et al. Long-term survival after videothoracoscopic lobectomy for stage I lung cancer. Chest 126 3 (2004) 725-732
119. Sebastien R., Marie-Christine E., Vincent B., et al. Laparoscope use and surgical site infections in digestive surgery. Annals of Surgery 247 4 (2008) 627-632
120. Sekhar N., Torquati A., Youssef Y., et al. A comparison of 399 open and 568 laparoscopic gastric bypasses performed during a 4-year period. Surgical Endoscopy 21 4 (2007) 665-668
121. Hinojosa M.W., Murrell Z.A., Konyalian V.R., et al. Comparison of laparoscopic vs open sigmoid colectomy for benign and malignant disease at academic medical centers. Journal of Gastrointestinal Surgery 11 11 (2007) 1423-1429 [discussion: 1429-30]
122. Pokala N., Sadhasivam S., Kiran R.P., et al. Complicated appendicitis-is the laparoscopic approach appropriate? A comparative study with the open approach: outcome in a community hospital setting. The American Surgeon 73 8 (2007) 737-741 [discussion: 741-2]
123. Sauerland S., Lefering R., and Neugebauer E.A.M. Laparoscopic versus open surgery for suspected appendicitis. Cochrane Database of Systematic Reviews 18 4 (2004) CD001546
124. Whitson B.A., D'Cunha J., and Maddaus M.A. Minimally invasive cancer surgery improves patient survival rates through less perioperative immunosuppression. Medical Hypotheses 68 6 (2007) 1328-1332
125. Fortis C., Ferrero E., Biffi M., et al. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation. Cancer Immunology, Immunotherapy: CII 33 2 (1991) 128-132
126. von Rohr A., Ghosh A.K., Thatcher N., et al. Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. British Journal of Cancer 67 1 (1993) 163-171
127. Aulitzky W.E., Schuler M., Peschel C., et al. Interleukins. Clinical pharmacology and therapeutic use. Drugs 48 5 (1994) 667-677
128. Angevin E., Valteau-Couanet D., Farace F., et al. Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer. Journal of Immunotherapy with Emphasis on Tumor Immunology 18 3 (1995) 188-195
129. Klatte T., Ittenson A., Rohl F.W., et al. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. British Journal of Cancer 95 9 (2006) 1167-1173
130. Mitchison N.A. Blood transfusion in fowl: an example of immunological tolerance requiring the persistence of antigen. Bulletin de la Société Internationale de Chirurgie 18 3 (1959) 257-273
131. Halasz N.A., and Orloff M.J. Antigen pretreatment and mechanisms of the resulting temporary tolerance. Proceedings of the Society for Experimental Biology and Medicine 116 (1964) 987-990
132. Danielson C.F., Filo R.S., O'Donnell J.A., et al. Institutional variation in hemotherapy for solid organ transplantation. [erratum appears in Transfusion 1996 Aug;36(8):764]. Transfusion (Paris) 36 3 (1996) 263-267
133. Chen G., Zhang F.J., Gong M., et al. Effect of perioperative autologous versus allogeneic blood transfusion on the immune system in gastric cancer patients. Journal of Zhejiang University. Science. B 8 8 (2007) 560-565
134. Carter J.J., and Whelan R.L. The immunologic consequences of laparoscopy in oncology. Surgical Oncology Clinics of North America 10 3 (2001) 655-677
135. Wildbrett P., Oh A., Carter J.J., et al. Increased rates of pulmonary metastases following sham laparotomy compared to CO2 pneumoperitoneum and the inhibition of metastases utilizing perioperative immunomodulation and a tumor vaccine. Surgical Endoscopy 16 8 (2002) 1162-1169
136. Carter J.J., Feingold D.L., Oh A., et al. Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice. Surgical Innovation 13 1 (2006) 41-47
137. Bohm M., Ittenson A., Philipp C., et al. Complex perioperative immuno-dysfunction in patients with renal cell carcinoma. The Journal of Urology 166 3 (2001) 831-836
138. Schinkel C., Licht K., Zedler S., et al. Perioperative treatment with human recombinant interferon-gamma: a randomized double-blind clinical trial. Shock 16 5 (2001) 329-333
139. Enesel M.B., Acalovschi I., Grosu V., et al. Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Research 25 6C (2005) 4583-4590
140. Oosterling S.J., van der Bij G.J., Mels A.K., et al. Perioperative IFN-alpha to avoid surgically induced immune suppression in colorectal cancer patients. Histology and Histopathology 21 7 (2006) 753-760
141. Licht A.K., Schinkel C., Zedler S., et al. Effects of perioperative recombinant human IFN-gamma (rHuIFN-gamma) application in vivo on T cell response. Journal of Interferon & Cytokine Research 23 3 (2003) 149-154
142. Weiss G., Meyer F., Matthies B., et al. Immunomodulation by perioperative administration of n-3 fatty acids. The British Journal of Nutrition 87 Suppl 1 (2002) S89-S94
143. Exner R., Tamandl D., Goetzinger P., et al. Perioperative GLY-GLN infusion diminishes the surgery-induced period of immunosuppression: accelerated restoration of the lipopolysaccharide-stimulated tumor necrosis factor-alpha response. Annals of Surgery 237 1 (2003) 110-115
144. Isaacs J.D. T cell immunomodulation-the Holy Grail of therapeutic tolerance. Current Opinion in Pharmacology 7 4 (2007) 418-425
145. Perkins B.A., and Bril V. Emerging therapies for diabetic neuropathy: a clinical overview. Current Diabetes Reviews 1 3 (2005) 271-280
146. Pollard L.C. Inhibiting costimulatory activation of T cells: a viable treatment option for rheumatoid arthritis?. Drugs 67 1 (2007) 1-9
147. Bibbo C., and Goldberg J.W. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot & Ankle International 25 5 (2004) 331-335